Daiichi's Acquisition of Ranbaxy
A basic introduction to the Daiiichi - Ranbaxy acquisition
RANBAXY LABORATORIES LIMITED
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, was an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It was incorporated in 1961 by Singh's grandfather Bhai Mohan Singh, further his son Dr. Parvinder Singh succeeded it, transforming Ranbaxy into India’s first multinational drug firm. It went public in 1973. In 1990 Ranbaxy Granted US patent for DoxyCyline. In 1992 Ranbaxy entered into an agreement with Eli Lilly & Co. of USA for setting up a joint venture in India to Market Select Lilly Products. It was Ranked 8th amongst the global generic pharmaceutical companies, its stated vision has been to be among the top five global generic players and to achieve global sales of $5 billion by 2012.
Ranbaxy had a presence in 23 of the top 25 pharmaceutical markets of the world. The Company had a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and served customers in over 125 countries. It had 12,000 employees, including 1,200 scientists. Mr. Atul Sobti was the then CEO & MD of Ranbaxy Laboratories at the time of the merger.
DAIICHI SANKYO COMPANY, LIMITED
Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of specialty chemicals. The Company entered into technical collaboration with the internationally known specialty chemicals manufacturer Dai-Ichi Kogyo Seiyaku Co. Limited of Kyoto, Japan (DKS) and commenced commercial production in 1963.
A global pharmacy innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies under the head of Takashi Shoda, CEO of Daiichi Sankyo. This integration created a more robust organization that allowed for
RANBAXY LABORATORIES LIMITED
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, was an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It was incorporated in 1961 by Singh's grandfather Bhai Mohan Singh, further his son Dr. Parvinder Singh succeeded it, transforming Ranbaxy into India’s first multinational drug firm. It went public in 1973. In 1990 Ranbaxy Granted US patent for DoxyCyline. In 1992 Ranbaxy entered into an agreement with Eli Lilly & Co. of USA for setting up a joint venture in India to Market Select Lilly Products. It was Ranked 8th amongst the global generic pharmaceutical companies, its stated vision has been to be among the top five global generic players and to achieve global sales of $5 billion by 2012.
Ranbaxy had a presence in 23 of the top 25 pharmaceutical markets of the world. The Company had a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and served customers in over 125 countries. It had 12,000 employees, including 1,200 scientists. Mr. Atul Sobti was the then CEO & MD of Ranbaxy Laboratories at the time of the merger.
DAIICHI SANKYO COMPANY, LIMITED
Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of specialty chemicals. The Company entered into technical collaboration with the internationally known specialty chemicals manufacturer Dai-Ichi Kogyo Seiyaku Co. Limited of Kyoto, Japan (DKS) and commenced commercial production in 1963.
A global pharmacy innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies under the head of Takashi Shoda, CEO of Daiichi Sankyo. This integration created a more robust organization that allowed for